Company overview
What does PHIBRO ANIMAL HEALTH CORP do?
PHIBRO ANIMAL HEALTH CORP (PAHC) is a U.S. SEC registrant. The Commission classifies the issuer under SIC 2834 (Pharmaceutical Preparations).
What does PHIBRO ANIMAL HEALTH CORP do?
PHIBRO ANIMAL HEALTH CORP (PAHC) is a U.S. SEC registrant. The Commission classifies the issuer under SIC 2834 (Pharmaceutical Preparations).
What industry is PHIBRO ANIMAL HEALTH CORP in?
Biotechnology · Pharmaceutical Preparations
What was PHIBRO ANIMAL HEALTH CORP's latest reported revenue?
$383.5M for Q1 2026, from 10-Q filed May 6, 2026.
What changed in the latest comparable period?
Revenue increased +10.3% ($347.8M to $383.5M; Q1 2025 vs Q1 2026).
Business model (from the public record)
Belvedere describes the business using the issuer’s SEC classification and the company description extracted from public filings. Segment mix, customer identity, and recurring-versus-transactional revenue are shown only when those facts are identified in the filing extract—not inferred.
Biotechnology · Pharmaceutical Preparations · United States
Financial profile
- Revenue
- $383.5M 10-Q · Q1 2026 · Filed May 6, 2026
- Revenue growth YoY
- +10.3% Belvedere calculation · 10-Q · Q1 2026 · Filed May 6, 2026
- Gross margin
- +32.8% Belvedere calculation · 10-Q · Q1 2026 · Filed May 6, 2026
- Operating margin
- +11.6% Belvedere calculation · 10-Q · Q1 2026 · Filed May 6, 2026
- Net income
- $24M 10-Q · Q1 2026 · Filed May 6, 2026
- Operating cash flow
- — Not identified in latest matched XBRL period
- Capex
- — Not identified in latest matched XBRL period
- Belvedere FCF
- — Not identified in latest matched XBRL period
- FCF margin
- — Not identified in latest matched XBRL period
- Cash
- $61.4M 10-K · Jun 30, 2026 · Filed Aug 26, 2026
- Debt
- — Not identified in latest matched XBRL period
- Net debt
- -$61.4M Belvedere calculation · 10-K · Jun 30, 2026 · Filed Aug 26, 2026
- Shares
- — Not identified in latest matched XBRL period
Balance sheet snapshot
Cash $61.4M. Identified debt —. Net debt -$61.4M. Missing debt tags are not treated as a zero-debt capital structure.
Financial information is derived from public filings and other identified sources. Belvedere calculations may differ from company-defined non-GAAP measures. See methodology and source notes. Valuation multiples are omitted because a licensed market-data provider is not configured.
Latest filings
| Form | Filed | Period | Accession | Source |
|---|---|---|---|---|
| DEF 14A | Sep 18, 2026 | Nov 3, 2026 | 0001104659-26-108939 | SEC |
| 8-K | Aug 26, 2026 | Aug 26, 2026 | 0001104659-26-101531 | SEC |
| 10-K | Aug 26, 2026 | Jun 30, 2026 | 0001104659-26-101493 | SEC |
| 8-K | Jul 28, 2026 | Jul 28, 2026 | 0001104659-26-087544 | SEC |
| 8-K | Jun 26, 2026 | Jun 25, 2026 | 0001104659-26-078323 | SEC |
| 8-K | May 6, 2026 | May 6, 2026 | 0001104659-26-056316 | SEC |
| 10-Q | May 6, 2026 | Mar 31, 2026 | 0001104659-26-056280 | SEC |
What changed
Each line is an arithmetic comparison of sourced facts. It is not a thesis.
Research view
Belvedere has not published an initiation or update on PHIBRO ANIMAL HEALTH CORP. Universe inclusion is not a rating, a forecast, or coverage in the sell-side sense.
Research Radar
| Kind | Change | Explanation | Source | Date |
|---|---|---|---|---|
| Cash | $61.4M | Cash and cash equivalents were $61.4M as of the latest reported balance-sheet date. | 10-K · CashAndCashEquivalentsAtCarryingValue | Aug 26, 2026 |
| Revenue | +10.3% | Revenue increased +10.3% ($347.8M to $383.5M; Q1 2025 vs Q1 2026). | 10-Q · RevenueFromContractWithCustomerExcludingAssessedTax | May 6, 2026 |
| Revenue acceleration | -10.6 pp | Quarterly revenue YoY growth moved from +20.9% to +10.3% (-10.6 percentage points). | 10-Q · BelvedereRevenueGrowthYoY | May 6, 2026 |
| Margin change | $0.328 | Reported gross margin was +32.8% in the latest comparable period. | 10-Q · BelvedereGrossMargin | May 6, 2026 |
Rankings
- Healthcare Companies by Revenue Growth · rank 3 · +10.3%
Industry context
PHIBRO ANIMAL HEALTH CORP is mapped to Biotechnology (Pharmaceutical Preparations) from SIC metadata on the SEC submission. Mapping is a classification convenience, not a claim that every peer is economically comparable.
Belvedere Research Profile
This measures researchable information characteristics. It is not investment advice, a credit rating, or a buy/sell/hold recommendation.
Presence of core income-statement, cash-flow and balance-sheet concepts in SEC XBRL.
Comparable-period revenue history and operating-result availability.
Availability of margin, cash-flow and per-share concepts used in screening.
SEC periodic reports, current reports, proxy statement and website identified in submissions.
Distinct filing years in the current archive window plus comparable prior-period revenue.
Risks
Belvedere does not manufacture generic risk language. Material risks are those the issuer discloses in its periodic reports, particularly Item 1A of the latest Form 10-K.
Open latest Form 10-K on SEC.govSources
- Source
- U.S. Securities and Exchange Commission
- Form
- 10-Q
- Period
- Q1 2026
- Filed
- May 6, 2026
- Accession
- 0001104659-26-056280
- Concept
- RevenueFromContractWithCustomerExcludingAssessedTax
- Source
- U.S. Securities and Exchange Commission
- Form
- 10-Q
- Period
- Q1 2026
- Filed
- May 6, 2026
- Accession
- 0001104659-26-056280
- Concept
- BelvedereRevenueGrowthYoY
(RevenueFromContractWithCustomerExcludingAssessedTax 2026-03-31 / RevenueFromContractWithCustomerExcludingAssessedTax 2025-03-31) - 1
View filing- Source
- U.S. Securities and Exchange Commission
- Form
- 10-K
- Period
- Jun 30, 2026
- Filed
- Aug 26, 2026
- Accession
- 0001104659-26-101493
- Concept
- CashAndCashEquivalentsAtCarryingValue
Disclosure
Belvedere Research publishes informational analysis. Nothing on this site is investment advice, an offer, or a solicitation to buy or sell any security.
This page is a company intelligence / data profile. It is not a research report unless a dated note is attached above. Rankings appearing here are independent of any issuer compensation.
Frequently asked questions
- What does PHIBRO ANIMAL HEALTH CORP do?
- PHIBRO ANIMAL HEALTH CORP (PAHC) is a U.S. SEC registrant. The Commission classifies the issuer under SIC 2834 (Pharmaceutical Preparations).
- What industry is PHIBRO ANIMAL HEALTH CORP in?
- PHIBRO ANIMAL HEALTH CORP is classified in Biotechnology (Pharmaceutical Preparations).
- When did PHIBRO ANIMAL HEALTH CORP last file a periodic report?
- PHIBRO ANIMAL HEALTH CORP last filed a 10-K on Aug 26, 2026 (accession 0001104659-26-101493).
- What was PHIBRO ANIMAL HEALTH CORP's latest revenue?
- $383.5M for Q1 2026, sourced from 10-Q filed May 6, 2026.
- Does Belvedere cover PHIBRO ANIMAL HEALTH CORP?
- PHIBRO ANIMAL HEALTH CORP is in the Belvedere universe. Presence in the universe is not the same as active initiation coverage.